The cancer drug price cap cleared its biggest hurdle on Thursday as the National Pharmaceutical Pricing Authority (NPPA) approved, in principle, a proposal to cap trade margins at 30 per cent of MRP for identified non-scheduled anti-cancer medicines — a move expected to cut prices by 20 to 70 per cent and save patients roughly Rs 2,500 crore every year.
The decision was taken at the 283rd overall and 151st meeting of the NPPA Authority under the Drugs (Prices Control) Order, 2013, chaired by Department of Pharmaceuticals Secretary Manoj Joshi. The Authority invoked Paragraph 19 of the DPCO, 2013 — the public-interest clause — noting that “extraordinary circumstances” warranted urgent intervention against excessive profiteering.
170% Average Markup, Up to 700% in Some Cases
NPPA’s market analysis found that non-scheduled anti-cancer drugs carry an average trade mark-up of about 170 per cent, with extreme cases exceeding 700 per cent. While scheduled essential medicines already face ceiling prices, non-scheduled formulations were only monitored to ensure annual price hikes stayed under 10 per cent — leaving a wide corridor for inflated margins across distributors, wholesalers and retailers.
The anti-cancer drugs market comprises nearly 225 drugs and 500 formulations with an annual turnover of around Rs 12,500 crore. Scheduled cancer drugs under price control account for only about Rs 2,250 crore; the balance is non-scheduled — precisely the segment this cancer drug price cap targets.
Supreme Court’s “Broad Daylight Dacoity” Rebuke
The decision follows sharp judicial criticism. A Supreme Court bench of Justices Vikram Nath and Sandeep Mehta had flagged exorbitant cancer medicine prices, describing them as “broad daylight dacoity” and “carnage, plain and simple,” while questioning the huge gap between what retailers pay and what patients are charged.
The NPPA has asked the Health Ministry to constitute an expert committee under the Directorate General of Health Services (DGHS) to finalise the list of drugs covered; the panel must submit its report by October 14. The 2019 precedent is encouraging: a 30 per cent cap on 42 selected non-scheduled anti-cancer medicines cut prices of 526 brands by roughly 50 per cent, saving patients an estimated Rs 984 crore a year. For context on how the government is reshaping indirect taxes on essentials, read our GST 2.0 reforms explainer.
What Happens Next
The approval is “in principle” — enforceable prices follow once the DGHS committee finalises the drug list and the NPPA issues its notification. The cap will cover branded, generic, domestic, imported, patented and non-patented products. Patient groups have welcomed the move but caution that the real test is implementation: the 2019 exercise worked because the drug list was specific and compliance was monitored.
With the expert panel’s October 14 deadline, the final list — and the first visible price cuts — should emerge within weeks. Also read: TCS Q2 results for the other big economic story of the week.
Frequently Asked Questions
How much will cancer drug prices fall?
The NPPA expects MRPs to fall broadly 20-70% depending on existing mark-ups, with estimated annual patient savings of around Rs 2,500 crore.
When will the cheaper cancer drug prices take effect?
A DGHS expert committee must finalise the covered drug list by October 14; the NPPA notification follows. The approval is currently "in principle."
What did the Supreme Court say about cancer drug prices?
Justices Vikram Nath and Sandeep Mehta called exorbitant pricing "broad daylight dacoity" and "carnage, plain and simple," questioning the gap between retailer cost and patient price.
Has India capped cancer drug margins before?
Yes — in February 2019, a 30% cap on 42 non-scheduled anti-cancer drugs cut 526 brands' prices by ~50%, saving patients an estimated Rs 984 crore annually.
